GH Research (GHRS) Interest Expenses (2021 - 2026)
GH Research (GHRS) posted quarterly Interest Expenses of -$179000.0 for Q4 2025, down 952.94% year-over-year from $20986.2 in Q4 2024, and down 752.38% quarter-over-quarter from -$21000.0 in Q3 2025.
Powered by 
Analysis
GH Research (GHRS) Interest Expenses (2021 - 2026) Analysis & Trends
GH Research's Interest Expenses history runs 5 years deep, the most recent figure standing at -$179000.0 for Q4 2025.
- In Q4 2025, Interest Expenses fell 952.94% year-over-year to -$179000.0; the TTM figure through Dec 2025 stood at $152000.0 (up 176.38% YoY), while the FY2025 annual figure was -$639000.0, up 11.62% from the prior year.
- Interest Expenses for Q4 2025 stood at -$179000.0, down from -$21000.0 in the prior quarter.
- The five-year high for Interest Expenses was $184000.0 in Q3 2023, with the low at -$246000.0 in Q1 2023.
- The 5-year median for Interest Expenses is -$4500.0 (2021), against an average of -$8937.5.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses jumped 418.18% in 2023, then plunged 952.94% in 2025.
- GH Research's Interest Expenses stood at $18000.0 in 2021, then climbed by 22.22% to $22000.0 in 2022, then surged by 418.18% to $114000.0 in 2023, then sank by 114.91% to -$17000.0 in 2024, then slumped by 952.94% to -$179000.0 in 2025.
- Business Quant data shows GHRS's Interest Expenses at -$179000.0 in Q4 2025, -$21000.0 in Q3 2025, and $174000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - | -83,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -83,000.00 |
| Mar 31, 2026 | -84,000.00 |
| Dec 31, 2025 | -90,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -174,000.00 |
| Mar 31, 2025 | -178,000.00 |
| Dec 31, 2024 | -179,000.00 |
| Sep 30, 2024 | -181,000.00 |
| Jun 30, 2024 | -178,000.00 |
| Mar 31, 2024 | -179,000.00 |
| Dec 31, 2023 | -189,000.00 |
| Sep 30, 2023 | -184,000.00 |
| Jun 30, 2023 | -179,000.00 |
| Mar 31, 2023 | -171,000.00 |
| Dec 31, 2022 | 123,000.00 |
| Sep 30, 2021 | -3,000.00 |
| Jun 30, 2021 | -6,000.00 |